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Abstract: Activated protein C (APC) is generated from the cleavage of protein C by thrombin coupled to throm-
bomodulin and, subsequently, is released as protein C activation peptide (papC). The aim of this study was to
evaluate the effect of papC on human dermal microvascular endothelial cells (HMEC-1), activated with 5 ng/
/mL TNF-a. Flow cytometry showed that papC inhibited the expression of VCAM-1 and ICAM-1, after activa-
tion with TNF-a. Similarly, RT-PCR analysis revealed that 2 and 4 pM papC inhibited the expression of VCAM-1
and IL-8 mRNA in TNF-a-treated HMEC-1. In addition, the expression of endothelial nitric oxide synthase
(eNOS) increased in HMEC-1 treated with papC, compared to those without treatment. Furthermore, Jurkat
cell adhesion to HMEC-1 induced by TNF-a was significantly inhibited after the addition of papC, compared to
HMEC-1 without papC (p = 0.03). Finally, a control peptide analog to papC showed no effect on the expression
of ICAM and VCAM on the surface of HMEC-1. In conclusion, our results suggest that papC exerts anti-
inflammatory effects on endothelial cells. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 3, 407–413)
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 Introduction
Activated protein C (APC) is generated physiologi-
cally on the endothelial cell surface due to the effect
of thrombin coupled to thrombomodulin [1]. Throm-
bin activates APC by cleavage between arginine-169
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and serine-170 with the subsequent release of the pro-
tein C activation peptide (papC), a 12-amino acid pep-
tide. The papC inhibits platelet aggregation in the
presence of epinephrine and thrombin [2]. APC pos-
sesses antihemostatic and antithrombotic effects and
participates in inflammation and apoptotic processes
[3–5]. Furthermore, protein C has anti-inflammatory
effects [5–7] and has been approved by the Federal
Drug Administration (USA) in severe sepsis therapy
[8]. APC inhibits the release of inflammatory cytok-
ines such as tumor necrosis factor-alpha (TNF-a), IL-6,
and IL-8 in experimental endotoxin-induced inflam-
mation [9]. Moreover, APC also limits leukocyte ad-
hesion to the endothelium and invasion into adjacent
tissues [10]. In an endothelial cell-based system, APC
inhibits a variety of inflammatory events in human
umbilical vascular endothelial cells, such as cell ad-
hesion molecule expression, cytokine production, and
necrosis factor-kB (NF-kB) nuclear translocation
[3, 8]; however, as of now, the specific role of papC in
the inflammatory process has not been evaluated.
Intercellular adhesion molecule 1 (ICAM-1) is
expressed at low concentrations on the membrane of
lymphocytes, monocytes, activated eosinophils, and
endothelial cells found in the microvasculature, but
not in large arteries or veins. ICAM-1 interacts with
leukocyte function-associated antigen-1 (LFA-1,
CD11a/CD18) and Mac-1 (CD11b), which are mem-
bers of the b2-integrin family. The main functions of
ICAM-1 are adhesion and trans-endothelial migra-
tion of leukocytes [11]; and it participates in T cell
activation [12]. The vascular cell adhesion molecule
1 (VCAM-1) is normally expressed by stimulated en-
dothelial cells; it participates in leukocyte adhesion
to endothelial cells and in signal pathways [13], and it
is expressed on the surface of human umbilical vein
endothelial cells (HUVEC).
TNF induces distinct gene expression programs
in microvascular and macrovascular human endothe-
lial cells [14]. Endothelial nitric oxide synthase
(eNOS) generates nitric oxide, an agent with chemo-
tactic and vessel-dilatatory effects during wound re-
pair. It also regulates collagen deposits, enhances an-
giogenesis, and regulates chemo-attractant cytokines.
IL-8 is a chemo-attractant and an activator of neu-
trophils, T cells, and other cells of the immune sys-
tem, and it is regulated by nitric oxide [15]. APC pro-
tects the endothelium by suppressing the inflamma-
tory process [16]. In addition, APC diminishes the
activation of leukocytes by suppressing E-selectin,
ICAM-1, VCAM-1, and the chemokine (C-X3-C mo-
tif) ligand 1 or fractalkine [15, 17]. In this paper, we
show that papC inhibits the synthesis and expression
of ICAM-1, VCAM-1, and IL-8, while increasing
eNOS synthesis in HMEC-1 stimulated with TNF-a;
moreover, papC inhibits the Jurkat cell adhesion to
HMEC-1 induced by TNF-a, suggesting that papC
has a potential role in inflammation.
Material and methods
papC and control peptides. The papC peptide (NH2-DT-
EDQEDQVDPR-COOH) and the control peptide
(NH2-ETEDQEDQVDPH-COOH) were obtained from In-
vitrogen (St. Louis, MO, USA). Both peptides were cus-
tom-synthesized for the authors. The control peptide was
designed by changing the terminal amino acids of papC,
taking into consideration the criteria for amino acid substi-
tutions by solvent exposure [18], and within nonaqueous en-
vironments [19]. The papC and the synthetic peptides used
as control were 95.4% pure by HPLC. For the biological as-
says, both peptides were dissolved in doubly-distilled water.
Cell culture. The endothelial cell line human dermal mi-
crovascular endothelial cells, HMEC-1, with a PBR-322-
based plasmid containing the coding region for the simian
virus 40 A gene product, was obtained from the National
Institute of Cardiology Ignacio Chavez (Mexico) and cul-
tured in 7% CO2 at 37°C in MCDB-131 medium (GIBCO
Laboratories, Fairfield, NJ, USA), supplemented with 15%
bovine fetal serum (Hyclone, Erembodegem-Belgium, Per-
bio Science Europe), 10 mM L-glutamine, 10 ng/mL en-
dothelial growth factor (EGF, Boehringer, Mannheim, Ger-
many), and l μg/mL water-soluble hydrocortisone (Sigma–
–Aldrich, USA). Cells were harvested every third day in
a solution containing 0.25% trypsin and 1 mM EDTA.
HMEC-1 activation and evaluation of ICAM-1 and VCAM-1
expression. HMEC-1 (200,000 cells/well) in six-well plates
(Costar, Cambridge, MA, USA) were stimulated with 5 ng/
/mL TNF-a (DakoCytomation, Glostrup, Denmark) as an
optimal dose for 6 h, 12 h, and 20 h. Experiments were per-
formed using 5 ng/mL TNF-a, simultaneously incubated in
the presence of either papC or the control peptide at 2 pM,
4 pM, or 6 pM, and the results were evaluated after 6 h, 12 h,
and 20 h. These experiments were performed ten times. To
evaluate the expression of ICAM-1 or VCAM-1 after expo-
sure to TNF-a in the presence of papC or control peptide,
the cells were detached with a solution of 0.25% trypsin and
1 mM Na-EDTA in PBS, washed with PBS, centrifuged at
200 g, and treated with 5% formalin in PBS for 5 min at
20°C. Then, the cells were washed in ice-cold PBS by cen-
trifugation (8 min at 4°C), and suspended in 2 mL of PBS
containing either 1 μg/100 μL phycoerythrin (PE)-conju-
gated mouse monoclonal anti-human VCAM-1/CD106
(FAB5649P, R&D Systems, Minneapolis, MN, USA) or
mouse anti-human ICAM-1 FITC conjugated monoclonal
antibody (CBL450F, Millipore Corporation, USA). After
incubation for 1 h at 20°C, the cells were washed with ice-
cold 1% BSA-PBS to remove the unbound antibody. The
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cell pellet was recovered by centrifugation (200 g, 8 min, at
4°C) and resuspended in 1 mL of cold BSA-PBS. After wash-
ing, the cells were treated with 2% p-formaldehyde for 30
min and washed with PBS before being analyzed by flow
cytometry with a FACScan flow cytometer (model FACS-
Calibur, Becton Dickinson, San Jose, CA, USA) with the
CellQuest analysis program (BD Biosciences, San Diego,
CA, USA). Flow cytometry was performed using the ap-
propriate single-stained samples for compensation setting.
The number of cells expressing adhesion molecules was
determined according to a forward light scatter/side light
scatter gating combined with an FL-1 channel for immun-
ostaining [20]. The mean fluorescence intensity (MFI) was
measured by flow cytometry, and the MFI ratio (MFIr)
was calculated by dividing the signal measured with the
antibody (Ab), anti-human VCAM-1 or anti-human
ICAM-1, with papC, by the signal measured without pep-
tide (MFIr = MFI Ab + papC/MFI Ab + without peptide
average) in order to take into account eventual background
differences [21].
RNA purification. All solutions used for RNA purification
were treated with 0.1% (v/v) diethyl pyrocarbonate (Sig-
ma–Aldrich, USA) and all glassware was autoclaved at 240°C
to remove RNAse traces. After a 12 h incubation period
with 6.0 pM papC in the presence or absence of TNF-a, the
500,000 HMEC-1/flask were lysed using Trizol according to
the manufacturer’s instructions (LifeTechnologies Inc.,
Carlsbad, CA, USA). The lysate was centrifuged at 233 g
for 20 min at 4°C with 200 μL of chloroform (Sigma–Ald-
rich, USA). The supernatant was discarded and the pellet
was suspended in 500 μL of a 75% (v/v) ethanol/water solu-
tion. Samples were mixed and incubated at room tempera-
ture for 2–3 min, centrifuged at 200 g for 10 min at 4°C, and
the aqueous phase was collected. RNA was precipitated with
equal volumes of isopropyl alcohol (Sigma–Aldrich, USA)
at 56°C for 10 min, shaken, and stored at –70°C. The integ-
rity of the RNA was evaluated with 1% agarose gel electro-
phoresis. The amount of RNA was evaluated at 260 nm and
the protein was determined at 280 nm. The relationship
between these two readings, approximately equal to 2, indi-
cated minimal protein contamination. Finally, 1% agarose
gel electrophoresis was used to evaluate the RNA integrity
in the sample.
RT-PCR analysis in TNF-a-induced HMEC-1 expression
of ICAM-1, VCAM-1, IL-8, and eNOS. We analyzed the
products from target mRNA (ICAM-1, VCAM-1, IL-8, and
eNOS), and one internal standard (b-actin). Briefly, target
RNA (1 μg) was converted to cDNA by treatment with re-
verse transcriptase and oligo (dT) primer, as follows: 100
pM of oligo dT, l μL of a mixture of deoxinucleotides
(dNTPs) (Promega, Madison, WI, USA), and 10 μL of ster-
ile water (Promega) were mixed. The mixture was incubat-
ed at 65°C for 5 min and at 4°C for 5 min before 2 μL of 0.1 M
dithiothreitol (Promega) and 4 μL of buffer 10 × M190A
Promega (10 mM Tris-HCl [pH 9.0 at 25°C]; 50 mM KCl;
0.1% Triton® X-100) were added to the mixture and then
incubated at 37°C for 2 min. Finally, 1 μL of avian myelo-
blastosis virus (AMV) and 200 U/μL of reverse transcriptase
(Promega) were incubated consecutively at 37°C for 50 min,
70°C for 15 min, and 4°C for 5 min; for PCR amplification,
1 μg of cDNA was used. Oligonucleotides were synthesized
in the Laboratory of Cellular Biology, National Institute of
Cardiology Ignacio Chavez (Mexico) with an automatic syn-
thesizer (Applied Biosystems 392/394 DNA synthesizers,
Carlsbad, CA, USA): ICAM-l sense 5’-TAT GGC AAC GAC
TCC TTC T-3’, anti-sense 5’-CAT TCA GCG TCA CCT
TGG-3’; for VCAM-1 sense 5’-ATG ACA TGC TTG ACC
AGG-3’, anti-sense 5’-GTG TCT CCT TCT TTG ACA CT-3’
[22]; for IL-8 sense 5’-CTC TCT TGG CAG CCT TCC
TGA-3’, anti-sense 5-CCC TCT GCA CCC AGT TTT CCT
T-3´ [23]; for eNOS sense 5’-CCA GCT AGC CAA AGT
CAC CAT-3’ and anti-sense 5’-GTCTCGGAG CCA TAC
AGG ATT-3’ [24]. Amplification was performed in a Px2
Thermal Cycler (Thermo Electron Corporation, Lexington,
KY, USA). We used b-actin as an internal control; the sense
primer was 5’-TAC-ATG-GCT-GGG-GTG-TTG-AA-3’ and
the sequence of the antisense primer was 5’-TCC AAG GGT
CCG CTG CAG GTC-3’, generating a 230-pb product. We
used 0.5 μL of Taq DNA polymerase (5 U/μL) (Altaenzymes,
St. Albert, Alberta, Canada). PCR conditions were as fol-
lows: ICAM-1: denaturation 95°C, 5 min; alignment 57.1°C,
1 min; elongation 72°C, 45 s. VCAM-1: denaturation 94°C,
5 min; alignment 56°C, 1 min; elongation 72°C, 1 min; eNOS:
denaturation 94°C, 45 s; alignment 55°C, 1 min, elongation
72°C, 2 min; b-actin: denaturation 94°C, 45 s; alignment 60°C,
45 s; elongation 72°C, 2 min. We performed 35 amplifica-
tion cycles for all molecules. DNA electrophoresis was per-
formed in 2% agarose gel containing 0.5 mg/mL ethidium
bromide (Sigma–Aldrich, USA). Gels were visualized and
photographed with a Chemi-Doc image analyzer (Bio-Rad,
Hercules, CA, USA). To compare band intensities, the gels
were scanned and analyzed with VisionWorksLS Analysis
Software (UVP, Upland, CA, USA). Analyses were per-
formed in triplicate.
Cell adhesion assays. Jurkat cells (CD3+ lymphoblasts) were
from the Laboratory of Cellular Biology, National Institute
of Cardiology Ignacio Chavez (Mexico). Jurkat cells were
cultured in RPMI-1640 medium, 10% fetal calf serum,
10 mM HEPES, and 2 mM L-glutamine (Sigma–Aldrich, USA)
at 37°C in 7% CO2. Jurkat cells (1.5 × 10
6 cells/mL) labeled
with BCECF-AM (Molecular Probes, Eugene, OR, USA)
in HEPES buffer (pH 7.2; Sigma–Aldrich, USA) were used
to identify adherent cells, according to the manufacturer’s
instructions [25]. Adhesion assays were carried out in
24-well tissue culture plates (Nalgene Nunc International,
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Rochester, NY, USA) seeded with 1 × 105 endothelial cells
cultured for 24 h to allow the formation of monolayers, be-
fore adding BCECF-AM-labeled Jurkat cells (3 × 105). The
cells were allowed to interact with HMEC-1 for 1 h; non-
adherent cells were removed by gently washing with HEPES
buffer (pH 7.2). Adhesion of Jurkat cells to HMEC was de-
termined by counting the number of Jurkat cells in five to
seven randomly selected fields (× 20), with an epi-fluores-
cence inverted microscope (Axiovert 200, Zeiss, Göttingen,
Germany). The effects of TNF-a, papC, and control peptide
on cellular adhesion were determined by adding TNF-a
(5 ng/mL), different concentrations of papC or the control
peptide (2–6 pM), or papC simultaneously with TNF-a
(5 ng/mL) to the cell monolayers, 12 h before adding the Ju-
rkat cells. The experiments were performed ten times and
the results were obtained by comparing the effect of TNF-a
on cellular adhesion in cells treated with papC or control pep-
tides, and reported as a percentage ± standard deviation (SD)
of the mean of cells that adhered to at least two Jurkat cells.
Statistical analysis. Data was expressed as the mean ± SD.
One-way ANOVA was used to analyze the effect of papC
on the expression of ICAM-1 and VCAM-1 in HMEC-1;
results with p values < 0.05 were considered significant.
Dunn’s multiple comparisons post-test was used to com-
pare adhesion molecules among different groups. The cal-
culations were performed with GraphPad Prism version 3.00
for Windows (GraphPad Software, San Diego, CA, USA;
www.graphpad.com).
Results
VCAM-1 and ICAM-1 expression
in the presence of papC
After HMEC-1 was stimulated with 5 ng/mL TNF-a
for 6 h, the expression of ICAM-1 was increased (MFI =
= 300.34), compared to HMEC-1 control cells not
stimulated with TNF-a (MFI = 158.86). However,
there was no significant difference between cells also
treated with 6.0 pM papC (MFIr = 0.99) or a control
peptide alone (MFIr = 1.00) after incubation for 6–
–20 h. The expression of ICAM-1 was lower at 12 h
(MFIr = 0.73) versus 20 h (MFIr = 0.99). Twelve
hours after the addition of 6.0 pM papC and TNF-a,
ICAM-1 expression in HMEC-1 cells was significantly
diminished (Figure 1A).
After stimulation of HMEC-1 with 5 ng/mL TNF-a
for 6 h, the expression of VCAM-1 was increased
(MFI = 400.97), compared to control cells not stim-
ulated with TNF-a (MFI = 200.10).
Similarly to ICAM-1, papC alone showed no effect
on VCAM-1 expression in HMEC-1 (MFIr = 0.98),
after exposure for 6–20 h (Figure 1B), which was com-
parable to control peptide treatment (MFIr 0.99) at
Figure 1. Expression of ICAM-1 and VCAM-1 in HMEC-1
cells with papC in the presence of TNF-a. (A) The expres-
sion of ICAM-1 (FITC) and (B) VCAM-1 (PE) in
HMEC-1, induced by TNF-a in the presence of papC,
was measured. In each determination, 5,000 cells were
evaluated. The mean fluorescence intensity (MFI) was
measured using a FACScan flow cytometer. The MFI ratio
(MFIr) was calculated by dividing the signal with the papC
antibody by the signal measured without peptide. The
Kruskal–Wallis Test with Dunn’s Multiple Comparison Test
was used to determine significance; *p < 0.05
6 h and 12 h (data not shown). After TNF-a exposure
with 6.0 pM papC for 12 h, VCAM-1 expression sig-
nificantly decreased, giving a MFIr of less than 0.2.
ICAM-1 and VCAM-1 mRNA expression
TNF-a was considered to be 100% expressed in stim-
ulated cells, compared to nonstimulated HMEC-l
(Figure 2). ICAM-1 and VCAM-1 mRNA expression
increased in HMEC-1 after stimulation with 5 ng/mL
TNF-a for 12 h. In contrast, the control peptide did
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Figure 2. The effect of TNF-a and papC on the expression
of ICAM-1, VCAM-1, IL-8, and eNOS mRNA in HMEC-1
cells. Lane 1: control assays with nonstimulated HMEC-1.
Lane 2: HMEC-1 cells treated with 5 ng/mL TNF-a. Lane 3:
HMEC-1 treated with 2 pM papC plus 5 ng/mL TNF-a. Lane
4: HMEC-1 treated with 4 pM papC plus 5 ng/mL TNF-a.
Lane 5: HMEC-1 treated with 6 pM papC plus 5 ng/mL
TNF-a. b-actin mRNA was used as an amplification control.
Results are representative samples from three replicates
not induce changes in ICAM-1 and VCAM-1 mRNA
expression (data not shown).
The expression of ICAM-1 mRNA was between 20%
and 40% less when the cells were incubated with 2 pM,
4 pM, or 6 pM papC and TNF-a, compared to TNF-a
stimulation alone. Similarly, VCAM-1 mRNA expression
was approximately 20% less when cells were simulta-
neously incubated with papC at 2 pM, 4 pM, or 6 pM and
TNF-a, compared to TNF-a stimulation alone. Howev-
er, a dose-dependent relationship was not observed.
 IL-8 mRNA expression
IL-8 mRNA expression was higher in cells stimulat-
ed with TNF-a after 12 h of incubation, compared to
nonstimulated cells, and that expression was consid-
ered as 100%. In contrast, control peptide did not
induce changes in IL-8 mRNA expression (data not
shown). HMEC-1 does not express IL-8 constitutive-
ly; therefore, the effect of papC on IL-8 expression
was determined after exposure to 5 ng/mL TNF-a.
When cells were simultaneously incubated with 2–6
pM papC and TNF-a, the IL-8 mRNA expression
was less than 5%, compared to HMEC-1 stimulated
with only 5 ng/mL TNF-a (Figure 2).
eNOS mRNA expression
Expression of eNOS mRNA in HMEC-1 decreased
by less than 5% after treatment with 5 ng/mL TNF-a,
compared to nontreated cells. In contrast, control
peptide did not induce changes in eNOS mRNA ex-
pression (data not shown). The expression of eNOS
mRNA increased by more than 30% in HMEC-1 cells
stimulated with TNF-a and in the presence of 2 pM,
4 pM, and 6 pM of papC (Figure 2).
Cellular adhesion in the presence of papC
HMEC-1 showed that basal adhesion to Jurkat cells
was less than 2%, whereas maximal adhesion
(85 ± 5%) was obtained with 5 ng/mL TNF-a. Basal
adhesion to Jurkat cells was not affected by papC. In
addition, adhesion to Jurkat cells was not significantly
affected by the presence of the control peptide. Also,
the control peptide did not exert a significant effect on
cell adhesion induced by TNF-a (data not shown). In
a TNF-a activated HMEC-1 cell layer, significant inhi-
bition of Jurkat adhesion to HMEC-1 cells in the pres-
ence of papC was observed. Specifically, 36 ± 5%, 34 ±
3%, and 18 ± 4% of Jurkat adhesion was achieved with
2 pM, 4 pM, and 6 pM papC, respectively (Figure 3).
Discussion
Protein C activation peptide (papC) is released from
protein C by thrombin, generating activated protein C
(APC). It has been shown that APC has cytoprotective
effects via inhibition of apoptosis and inflammation in
humans and animals [26]; in addition, it is able to inhibit
cytokine signaling and the expression of cell-surface
adhesion molecules. APC inhibits neutrophil adhesion
to and migration from extracellular matrix proteins by
binding to the b1 and b3 integrins of neutrophils [27]. It
has been suggested that papC could alter the inflamma-
tory process by inhibiting thrombin-induced platelet
aggregation [28]. In this research, we showed that papC
exerts anti-inflammatory effects on the endothelial cell
line HMEC-1 by inhibiting the expression of adhesion
molecules ICAM-1, VCAM-1, and IL-8.
In this investigation, we evaluated the effect of
papC in HMEC-1 because this cell line preserves the
morphology, phenotype, and several characteristics
of normal microvascular endothelial cells when acti-
vated with TNF-a [29]. ICAM-1 is a constitutive mol-
ecule of HMEC-1 and its expression increases after
appropriate stimulation. After incubating HMEC-1
with 5 ng/mL TNF-a plus 6.0 pM papC, the expres-
sion of ICAM-1 mRNA decreased steadily compared
to cells that were activated with TNF-a alone. ICAM-1
participates as a receptor for LFA-1, a b2-integrin ex-
pressed on neutrophils, monocytes, lymphocytes, and
natural killer cells, a fact that may explain the inhibi-
tion of Jurkat cell adhesion in the presence of papC.
The adhesion of Jurkat cells to HMEC-1 shows
a dose-dependent effect, since higher doses of papC
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resulted in a higher inhibition of adhesion. The inhi-
bition observed in the adhesion test correlated with
the inhibition observed in the expression of ICAM-1
and VCAM-1, which are involved in the adhesion of
endothelial cells during the inflammatory process.
VCAM-1 is an inducible membrane receptor that
interacts with Very Late Antigen-4 (VLA-4) and it is
expressed only after endothelial cell activation. In
addition, APC down-regulates VCAM-1 transcription
[28]. The papC sequence lacks the RGD sequence,
a key motif of APC for its interaction with neutrophil
integrins. However, it is interesting to note that papC
as well as APC induced inhibition of VCAM-1 at 12 h,
thus suggesting a regulatory effect of this peptide on
leukocyte adhesion by integrin-independent mecha-
nisms [23]. It has been shown that activated APC
ameliorates the TNF-a-induced inflammatory re-
sponse of endothelium via the endothelial APC re-
ceptor. Hence, the possibility that the endothelium
has specific receptors for papC should not be ruled
out [30]. The pap C in vascular endothelium as well
as in platelets has shown dose-dependent effects, sug-
gesting that specific receptors for papC could be
present in different cells [2].
Neutrophil recruitment across the endothelium is
mainly due to concentration gradients of IL-8, an in-
terleukin synthesized by the endothelium in response
to inflammatory signals such as TNF-a [31]. TNF-a
induces IL-8 expression in both HUVEC and HMEC-1
[29]. The expression of IL-8 by the HMEC-1 cell line
induced by TNF-a decreased in the presence of papC.
In addition, endothelial cells constitutively express
eNOS, which can be down-regulated by cytokines such
as TNF-a [32]; and down-regulation of eNOS is a cru-
cial mechanism that results in endothelial dysfunc-
tion [33].
Thus, our experiments suggest that papC exerts
anti-inflammatory effects on endothelial cells by pro-
moting inhibition of cytokine signaling and adhesion
molecule expression. The adhesion between Jurkat
cells and HMEC-1 was reduced in the presence of
papC compared to the control peptide with TNF-a,
suggesting that papC is able to modulate the expres-
sion of molecules involved in inflammatory and cell-
cell adhesion processes. The intrinsic signaling net-
works of the coagulation pathways have recently
emerged as relevant determinants for survival in sep-
sis and systemic inflammatory response syndromes
[34, 35]. Therefore, the release of papC after APC
cleavage could represent an alternative to regulate
the pro-inflammatory process.
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